IP Library Granted Patent US 11,873,298
Granted Patent B2
US 11,873,298 · App. 16/758,495 · Granted Jan 16, 2024

Compounds and uses thereof

Inventors: Matthew Lucas (Lexington, MA); Bertrand Le Bourdonnec (Northborough, MA); Iwona Wrona (Sharon, MA); Bhaumik Pandya (Bedford, MA); Parcharee Tivitmahaisoon (Boston, MA); Kerem Ozboya (Cambridge, MA); Benjamin Vincent (Cambridge, MA); Daniel Tardiff (Arlington, MA); Jeff Piotrowski (Somerville, MA); Eric Solis (Milford, MA); Robert Scannevin (Hopkinton, MA); Chee-Yeun Chung (Brookline, MA); Rebecca Aron (Cambridge, MA); Kenneth Rhodes (Belmont, MA)
Assignee: JANSSEN PHARMACEUTICA NV
C07D413/14C07D271/07C07D413/04C07D413/10C07D417/04C07D417/14C07D471/04C07D487/04C07D487/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,873,298
App. No.
16/758,495
Granted
Jan 16, 2024
Kind
B2
Abstract

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Claims (22)

1. A compound, or pharmaceutically acceptable salt thereof, having the structure of any one of the following compounds:

#

Structure

1241

1238

1237

1236

1232

1231

1228

1227

1226

1225

1110

1111

2. A pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt thereof, of claim 1 , and a pharmaceutically acceptable excipient.

3. A method of alleviating the symptoms associated with a neurological disorder in a subject in need thereof, the method comprising administering an effective amount of a compound, or pharmaceutically acceptable salt thereof, of claim 1 .

4. A method of inhibiting toxicity in a cell related to a protein, the method comprising administering an effective amount of a compound, or pharmaceutically acceptable salt thereof, of claim 1 .

5. The method of claim 4 , wherein the toxicity is α-synuclein -related toxicity.

6. The method of claim 4 , wherein the toxicity is ApoE4-related toxicity.

7. The method of claim 4 , wherein the cell is a mammalian neural cell.

8. A method of alleviating the symptoms associated with a stearoyl-CoA desaturase (SCD)-associated disorder in a subject in need thereof, the method comprising administering an effective amount of a compound, or pharmaceutically acceptable salt thereof, of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2022
From: YUMANITY THERAPEUTICS, INC.; YUMANITY, INC.
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 062148/0414 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2020
From: LUCAS, MATTHEW; LE BOURDONNEC, BERTRAND; WRONA, IWONA; PANDYA, BHAUMIK; TIVITMAHAISOON, PARCHAREE; OZBOYA, KEREM; VINCENT, BENJAMIN; TARDIFF, DANIEL; PIOTROWSKI, JEFF; SOLIS, ERIC; SCANNEVIN, ROBERT; CHUNG, CHEE-YEUN; ARON, REBECCA; RHODES, KENNETH
To: YUMANITY THERAPEUTICS, INC.
Reel/Frame 053511/0730 →
Continuity (3)
Provisional Application 62662424 · Apr 25, 2018
Provisional Application 62576591 · Oct 24, 2017
Related Publication 20200262828A1 · Aug 20, 2020